Table 3. Countries that previously carried out MDA for LF.
| Country | Primary vector | Treatment α | At-risk population, 2012 ¤ | Population growth rate, 2012 ¥ | Previous effective years ¤ | Scale-up schedule ± |
|---|---|---|---|---|---|---|
| >50% targeted | ||||||
| Burkina Faso | Anopheles | IVM + ALB | 16,779,208 | 2.9% | 11 | 1/1/1/0 |
| Cameroon | Anopheles | IVM + ALB | 17,091,469 | 2.5% | 5 | 1/1/1/0 |
| Côte d'Ivoire | Anopheles | IVM + ALB | 14,000,000 | 2.3% | 1 | 1/1/1/0 |
| Comoros | Culex | DEC + ALB | 514,110 | 2.4% | 5 | 1/1/1/0 |
| Egypt | Culex | DEC + ALB | 536,443 | 1.7% | 11 | 1/1/1/0 |
| Fiji | Aedes | DEC + ALB | 529,984 | 0.8% | 7 | 1/1/1/0 |
| French Polynesia | Aedes | DEC + ALB | 274,544 | 1.1% | 10 | 1/1/1/0 |
| Ghana | Anopheles | IVM + ALB | 11,925,399 | 2.2% | 11 | 1/1/1/0 |
| Haiti | Culex | DEC + ALB | 10,732,356 | 1.4% | 10 | 1/1/1/0 |
| India | Culex | DEC + ALB | 617,170,000 | 1.3% | 15 | 1/1/1/0 |
| Kenya | Culex * | DEC + ALB | 3,421,741 | 2.7% | 3 | 1/1/1/0 |
| Lao PDR | Culex * | DEC + ALB | 132,644 | 1.9% | 2 | 1/1/1/0 |
| Liberia | Anopheles | IVM + ALB | 3,600,000 | 2.7% | 0 | 1/1/1/0 |
| Malawi | Anopheles | IVM + ALB | 14,807,685 | 2.9% | 5 | 1/1/1/0 |
| Mali | Anopheles | IVM + ALB | 16,166,882 | 3.0% | 7 | 1/1/1/0 |
| Mozambique | Anopheles | IVM + ALB | 17,114,949 | 2.5% | 3 | 1/1/1/0 |
| Nepal | Culex | DEC + ALB | 15,755,990 | 1.2% | 10 | 1/1/1/0 |
| Niger | Anopheles | IVM + ALB | 12,467,592 | 3.8% | 4 | 1/1/1/0 |
| Philippines | Aedes | DEC + ALB | 29,383,286 | 1.7% | 9 | 1/1/1/0 |
| Samoa | Aedes | DEC + ALB | 186,649 | 0.8% | 5 | 1/1/1/0 |
| Sierra Leone | Anopheles | IVM + ALB | 6,667,687 | 1.9% | 5 | 1/1/1/0 |
| Thailand | Aedes | DEC + ALB | 73,495 | 0.3% | 11 | 1/1/1/0 |
| Tuvalu | Aedes | DEC + ALB | 10,373 | 0.2% | 4 | 1/1/1/0 |
| Uganda | Anopheles | IVM + ALB | 14,464,244 | 3.4% | 5 | 1/1/1/0 |
| 30–50% targeted | ||||||
| Dominican Republic | Culex | DEC + ALB | 249,803 | 1.3% | 6 | 2/2/1/0 |
| Guyana | Culex | DEC + ALB | 690,869 | 0.6% | 2 | 2/2/1/0 |
| Indonesia | Culex | DEC + ALB | 113,283,453 | 1.2% | 7 | 2/2/1/0 |
| Myanmar | Culex | DEC + ALB | 41,666,403 | 0.8% | 9 | 2/2/1/0 |
| Timor Leste | Anopheles | DEC + ALB | 1,180,067 | 2.9% | 3 | 2/2/1/0 |
| United Republic of Tanzania | Culex | IVM + ALB | 45,173,251 | 3.0% | 11 | 2/2/1/0 |
| 20–30% targeted | ||||||
| Bangladesh | Culex | DEC + ALB | 77,230,000 | 1.2% | 14 | 3/3/1/0 |
| Benin | Anopheles | IVM + ALB | 3,747,913 | 2.7% | 11 | 3/3/1/0 |
| Guinea Bissau | Anopheles | IVM + ALB | 1,582,496 | 2.4% | 1 | 3/3/1/0 |
| Malaysia | Anopheles | DEC + ALB | 1,266,123 | 1.7% | 7 | 3/3/1/0 |
| Nigeria | Anopheles | IVM + ALB | 108,526,381 | 2.8% | 5 | 3/3/1/0 |
| <20% targeted | ||||||
| Brazil | Culex | DEC | 1,700,000 | 0.9% | 4 | 4/4/1/0 |
| Ethiopia | * Culex | IVM + ALB | 30,000,000 | 2.6% | 4 | 4/4/1/0 |
| Kiribati | Culex | DEC + ALB | 103,058 | 1.5% | 5 | 4/4/1/0 |
| Madagascar | Anopheles | DEC + ALB | 18,602,379 | 2.8% | 6 | 4/4/1/0 |
| Micronesia | Aedes | DEC + ALB | 11,241 | 0.1% | 1 | 4/4/1/0 |
| Papua New Guinea | Anopheles | DEC + ALB | 5,602,188 | 2.2% | 1 | 4/4/1/0 |
| Senegal | Anopheles | IVM + ALB | 5,314,600 | 2.9% | 3 | 4/4/1/0 |
*Treatment durations for Culex spp. were used for countries in which primary vector species was unknown.
αTreatment assumed to occur once annually using diethylcarbamazine citrate (DEC) and albendazole (ALB), or in areas co-endemic with onchocerciasis, ivermectin (IVM) and albendazole (ALB)
¤ Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. Available from: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
¥ United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.227.
± Refers to MDA schedules assumed to be used by these countries for the purposes of our analysis for the global elimination scenario, eradication I, eradication II, and eradication III scenarios, respectively. In schedule I, two deciles (20%) of the at-risk population are added to the MDA schedule annually. In schedule II, one decile is added annually. In schedule III, one decile is added every 2 years, and in schedule IV, one decile is added every 3rd year (see: Rate of Scale-Up and History of Control). ‘0’ refers to instantaneous scale-up.